Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Completed · Phase 1
Conditions studied: Ovarian Neoplasms
In brief
Anetumab ravtansine is developed for the treatment of patients with recurrent platinum-resistant ovarian cancer. The purpose of the proposed trial is to identify the maximum tolerated dose of anetumab ravtansine that could be safely combined with pegylated liposomal doxorubicin in this indication.
Key facts
- Study ID
- NCT02751918
- Run by
- Bayer
- People needed
- 65
- Starts
- 2016-06-08
- Expected to finish
- 2019-10-31
- Last updated by the study team
- 2019-11-22
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Subjects with locally invasive or metastatic, epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Subjects must provide samples of tumor tissue
- Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not qualify if…
- Subjects with low-grade ovarian, fallopian tube, or Primary peritoneal cancer
- Women who are pregnant or breast feeding
- Subjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocol
Where it is running
- Rocky Mountain Cancer Centers — Aurora, Colorado, United States
- Yale University School of Medicine — New Haven, Connecticut, United States
- Oklahoma University Health Science Center — Oklahoma City, Oklahoma, United States
- UZ Leuven Gasthuisberg — Leuven, Belgium
- The Institute of Oncology — Chisinau, Moldova
- Ciutat Sanitària i Universitaria de la Vall d'Hebron — Barcelona, Spain
- Clinica Universidad de Navarra CUN en Madrid — Madrid, Spain
- Clínica Universidad de Navarra CUN — Pamplona, Spain
- Instituto Valenciano de Oncología — Valencia, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.